[{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Smoflipid","moa":"Homeostasis","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"St. Joseph's Healthcare Hamilton","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"St. Joseph's Healthcare Hamilton","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"St. Joseph's Healthcare Hamilton \/ Bausch Health","highestDevelopmentStatusID":"11","companyTruncated":"St. Joseph's Healthcare Hamilton \/ Bausch Health"},{"orgOrder":0,"company":"St. Joseph's Healthcare Hamilton","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"St. Joseph's Healthcare Hamilton","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"St. Joseph's Healthcare Hamilton \/ Bausch Health","highestDevelopmentStatusID":"11","companyTruncated":"St. Joseph's Healthcare Hamilton \/ Bausch Health"},{"orgOrder":0,"company":"Alvogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Phentermine","moa":"Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Alvogen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Alvogen \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Alvogen \/ Inapplicable"},{"orgOrder":0,"company":"Promomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Promomed","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Promomed \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Promomed \/ Inapplicable"},{"orgOrder":0,"company":"Laval University","sponsor":"OmniActive Health Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Capsimax","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Laval University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laval University \/ OmniActive Health Technologies","highestDevelopmentStatusID":"11","companyTruncated":"Laval University \/ OmniActive Health Technologies"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of Pennsylvania \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"University of Pennsylvania \/ Novo Nordisk"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eli Lilly | National Institute on Minority Health and Health Disparities","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ Eli Lilly | National Institute on Minority Health and Health Disparities","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Eli Lilly | National Institute on Minority Health and Health Disparities"},{"orgOrder":0,"company":"University of Melbourne","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"University of Melbourne","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Melbourne \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"University of Melbourne \/ Eli Lilly"},{"orgOrder":0,"company":"Western University, Canada","sponsor":"London Health Sciences Centre Research Institute (Lawson) | Queen Elizabeth II Health Sciences Centre | St. Michael's Hospital (Toronto, Canada)","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Western University, Canada","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Western University, Canada \/ London Health Sciences Centre Research Institute (Lawson) | Queen Elizabeth II Health Sciences Centre | St. Michael's Hospital (Toronto, Canada)","highestDevelopmentStatusID":"11","companyTruncated":"Western University, Canada \/ London Health Sciences Centre Research Institute (Lawson) | Queen Elizabeth II Health Sciences Centre | St. Michael's Hospital (Toronto, Canada)"},{"orgOrder":0,"company":"Ali Aminian","sponsor":"Ethicon","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Ali Aminian","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ali Aminian \/ Ethicon","highestDevelopmentStatusID":"11","companyTruncated":"Ali Aminian \/ Ethicon"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"National Institutes of Health | National Institute of Diabetes and Digestive and Kidney Diseases | Phenomix Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ National Institutes of Health | National Institute of Diabetes and Digestive and Kidney Diseases | Phenomix Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Mayo Clinic \/ National Institutes of Health | National Institute of Diabetes and Digestive and Kidney Diseases | Phenomix Sciences"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Clinolipid","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Baxter Healthcare Corporation \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Inapplicable"},{"orgOrder":0,"company":"University of Illinois, Chicago","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Imipenem","moa":"Bacterial penicillin-binding protein","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"University of Illinois, Chicago","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Illinois, Chicago \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University of Illinois, Chicago \/ Merck & Co"},{"orgOrder":0,"company":"Danone Specialized Nutrition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Fortimel","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Danone Specialized Nutrition","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danone Specialized Nutrition \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Danone Specialized Nutrition \/ Inapplicable"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"Orexigen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oslo University Hospital \/ Orexigen Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"Oslo University Hospital \/ Orexigen Therapeutics"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"Johns Hopkins University | Kaiser Permanente | HealthPartners Institute | University of Texas Health Science Center at Houston | Biomedical Research Institute of New Mexico | WW International Inc | KVK.Tech | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Phentermine Hydrochloride","moa":"Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wake Forest University Health Sciences \/ Johns Hopkins University | Kaiser Permanente | HealthPartners Institute | University of Texas Health Science Center at Houston | Biomedical Research Institute of New Mexico | WW International Inc | KVK.Tech | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"11","companyTruncated":"Wake Forest University Health Sciences \/ Johns Hopkins University | Kaiser Permanente | HealthPartners Institute | University of Texas Health Science Center at Houston | Biomedical Research Institute of New Mexico | WW International Inc | KVK.Tech | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Currax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Currax","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Currax \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Currax \/ Inapplicable"},{"orgOrder":0,"company":"Michelle Cardel, PhD, MS, RD","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bupropion Hydrochloride","moa":"Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Michelle Cardel, PhD, MS, RD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Michelle Cardel, PhD, MS, RD \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Michelle Cardel, PhD, MS, RD \/ Inapplicable"},{"orgOrder":0,"company":"Laval University","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Laval University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laval University \/ Bausch Health","highestDevelopmentStatusID":"11","companyTruncated":"Laval University \/ Bausch Health"},{"orgOrder":0,"company":"The Royal's Institute of Mental Health Research","sponsor":"University of Ottawa | The Royal Ottawa Mental Health Centre | Bausch Health | CHEO Research Institute | LEAF Weight Management Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bupropion Hydrochloride","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"The Royal's Institute of Mental Health Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Royal's Institute of Mental Health Research \/ University of Ottawa | The Royal Ottawa Mental Health Centre | Bausch Health | CHEO Research Institute | LEAF Weight Management Clinic","highestDevelopmentStatusID":"11","companyTruncated":"The Royal's Institute of Mental Health Research \/ University of Ottawa | The Royal Ottawa Mental Health Centre | Bausch Health | CHEO Research Institute | LEAF Weight Management Clinic"},{"orgOrder":0,"company":"St Andrew's Healthcare","sponsor":"Loughborough University","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"St Andrew's Healthcare","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"St Andrew's Healthcare \/ Loughborough University","highestDevelopmentStatusID":"11","companyTruncated":"St Andrew's Healthcare \/ Loughborough University"},{"orgOrder":0,"company":"Certmedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Polyglucosamine","moa":"Homeostasis","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Certmedica","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Certmedica \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Certmedica \/ Inapplicable"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mayo Clinic \/ Undisclosed"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Sponsor :
London Health Sciences Centre Research Institute (Lawson) | Queen Elizabeth II Health Sciences Centre | St. Michael's Hospital (Toronto, Canada)
Sponsor :
London Health Sciences Centre Research Institute (Lawson) | Queen Elizabeth II Health Sciences Centre | St. Michael's Hospital (Toronto, Canada)